Skip to main content
Top
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study

Authors: Michelle D. Robinson, Ina Mishra, Sneha Deodhar, Vipulkumar Patel, Katrina V. Gordon, Raul Vintimilla, Kim Brown, Leigh Johnson, Sid O’Bryant, David P. Cistola

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

Metabolic syndrome (MetS) is a highly prevalent condition that identifies individuals at risk for type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Prevention of these diseases relies on early detection and intervention in order to preserve pancreatic β-cells and arterial wall integrity. Yet, the clinical criteria for MetS are insensitive to the early-stage insulin resistance, inflammation, cholesterol and clotting factor abnormalities that characterize the progression toward type 2 diabetes and atherosclerosis. Here we report the discovery and initial characterization of an atypical new biomarker that detects these early conditions with just one measurement.

Methods

Water T2, measured in a few minutes using benchtop nuclear magnetic resonance relaxometry, is exquisitely sensitive to metabolic shifts in the blood proteome. In an observational cross-sectional study of 72 non-diabetic human subjects, the association of plasma and serum water T2 values with over 130 blood biomarkers was analyzed using bivariate, multivariate and logistic regression.

Results

Plasma and serum water T2 exhibited strong bivariate correlations with markers of insulin, lipids, inflammation, coagulation and electrolyte balance. After correcting for confounders, low water T2 values were independently and additively associated with fasting hyperinsulinemia, dyslipidemia and subclinical inflammation. Plasma water T2 exhibited 100% sensitivity and 87% specificity for detecting early insulin resistance in normoglycemic subjects, as defined by the McAuley Index. Sixteen normoglycemic subjects with early metabolic abnormalities (22% of the study population) were identified by low water T2 values. Thirteen of the 16 did not meet the harmonized clinical criteria for metabolic syndrome and would have been missed by conventional screening for diabetes risk. Low water T2 values were associated with increases in the mean concentrations of 6 of the 16 most abundant acute phase proteins and lipoproteins in plasma.

Conclusions

Water T2 detects a constellation of early abnormalities associated with metabolic syndrome, providing a global view of an individual’s metabolic health. It circumvents the pitfalls associated with fasting glucose and hemoglobin A1c and the limitations of the current clinical criteria for metabolic syndrome. Water T2 shows promise as an early, global and practical screening tool for the identification of individuals at risk for diabetes and atherosclerosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351–75.CrossRefPubMed Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351–75.CrossRefPubMed
2.
go back to reference Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313:1973–4.CrossRefPubMed Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313:1973–4.CrossRefPubMed
3.
go back to reference Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;14:E24.CrossRefPubMedPubMedCentral Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;14:E24.CrossRefPubMedPubMedCentral
4.
go back to reference Alberti KG, Eckel RH, Grundy SM. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation. 2009;120:1640–5.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation. 2009;120:1640–5.CrossRefPubMed
5.
go back to reference Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després J, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MRG, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM. The cardiometabolic health alliance. J Am Coll Cardiol. 2015;66:1050–67.CrossRefPubMed Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després J, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MRG, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM. The cardiometabolic health alliance. J Am Coll Cardiol. 2015;66:1050–67.CrossRefPubMed
7.
go back to reference Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care. 2005;28:2289–304.CrossRefPubMed Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care. 2005;28:2289–304.CrossRefPubMed
10.
go back to reference Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002;51:3120–7.CrossRefPubMed Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002;51:3120–7.CrossRefPubMed
11.
go back to reference Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.CrossRefPubMed Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.CrossRefPubMed
12.
go back to reference Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM, San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26:3153–9.CrossRefPubMed Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM, San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26:3153–9.CrossRefPubMed
13.
go back to reference Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.CrossRefPubMed Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.CrossRefPubMed
14.
go back to reference Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–9.CrossRefPubMed Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–9.CrossRefPubMed
15.
go back to reference Alberti KGMM, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabetic Med. 2007;24:451–63.CrossRefPubMed Alberti KGMM, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabetic Med. 2007;24:451–63.CrossRefPubMed
16.
go back to reference Napoli C, Crudele V, Soricelli A, Al-Omran M, Vitale N, Infante T, Mancini FP. Primary prevention of atherosclerosis. Circulation. 2012;125:2363–73.CrossRefPubMed Napoli C, Crudele V, Soricelli A, Al-Omran M, Vitale N, Infante T, Mancini FP. Primary prevention of atherosclerosis. Circulation. 2012;125:2363–73.CrossRefPubMed
17.
go back to reference DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318–68.CrossRefPubMed DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318–68.CrossRefPubMed
18.
go back to reference DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.CrossRefPubMed DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.CrossRefPubMed
19.
go back to reference Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89–94.CrossRefPubMed Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89–94.CrossRefPubMed
20.
go back to reference Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19.CrossRefPubMed Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19.CrossRefPubMed
21.
go back to reference Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab. 2005;7:2–8.CrossRefPubMed Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab. 2005;7:2–8.CrossRefPubMed
23.
go back to reference Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care. 2007;30:753–9.CrossRefPubMed Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care. 2007;30:753–9.CrossRefPubMed
24.
go back to reference Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study. Diabetes. 2006;55:1430–5.CrossRefPubMed Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study. Diabetes. 2006;55:1430–5.CrossRefPubMed
25.
go back to reference DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96:2354–66.CrossRefPubMed DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96:2354–66.CrossRefPubMed
26.
go back to reference McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460–4.CrossRefPubMed McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460–4.CrossRefPubMed
28.
go back to reference Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183–6.CrossRefPubMed Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183–6.CrossRefPubMed
29.
go back to reference Festa A, D’Agostino R Jr, Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131–7.CrossRefPubMed Festa A, D’Agostino R Jr, Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131–7.CrossRefPubMed
30.
32.
go back to reference Hulley SB, Cummings SR, Browner WS. Designing clinical research: an epidemiologic approach. Philadelphia: Williams & Wilkins; 1988. Hulley SB, Cummings SR, Browner WS. Designing clinical research: an epidemiologic approach. Philadelphia: Williams & Wilkins; 1988.
34.
go back to reference O’Bryant SE, Johnson L, Reisch J, Edwards M, Hall J, Barber R, Devous MDS, Royall D, Singh M. Risk factors for mild cognitive impairment among Mexican Americans. Alzheimers Dement. 2013;9(622–631):e1. O’Bryant SE, Johnson L, Reisch J, Edwards M, Hall J, Barber R, Devous MDS, Royall D, Singh M. Risk factors for mild cognitive impairment among Mexican Americans. Alzheimers Dement. 2013;9(622–631):e1.
35.
go back to reference Robinson MD, Cistola DP. Nanofluidity of fatty acid hydrocarbon chains as monitored by benchtop time-domain nuclear magnetic resonance. Biochemistry. 2014;53:7515–22.CrossRefPubMed Robinson MD, Cistola DP. Nanofluidity of fatty acid hydrocarbon chains as monitored by benchtop time-domain nuclear magnetic resonance. Biochemistry. 2014;53:7515–22.CrossRefPubMed
36.
go back to reference Motulsky H. Intuitive biostatistics: a nonmathematical guide to statistical thinking. New York: Oxford University Press; 2014. Motulsky H. Intuitive biostatistics: a nonmathematical guide to statistical thinking. New York: Oxford University Press; 2014.
37.
39.
go back to reference Wilcox RR, Keselman HJ. Modern regression methods that can substantially increase power and provide a more accurate understanding of associations. Eur J Pers. 2012;26:165–74.CrossRefPubMed Wilcox RR, Keselman HJ. Modern regression methods that can substantially increase power and provide a more accurate understanding of associations. Eur J Pers. 2012;26:165–74.CrossRefPubMed
40.
go back to reference American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40:S11–24.CrossRef American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40:S11–24.CrossRef
41.
go back to reference Huber PJ. Robust estimation of a location parameter. Ann Math Statist. 1964;35:73–101.CrossRef Huber PJ. Robust estimation of a location parameter. Ann Math Statist. 1964;35:73–101.CrossRef
42.
go back to reference Taylor EN, Forman JP, Farwell WR. Serum anion gap and blood pressure in the national health and nutrition examination survey. Hypertension. 2007;50:320–4.CrossRefPubMed Taylor EN, Forman JP, Farwell WR. Serum anion gap and blood pressure in the national health and nutrition examination survey. Hypertension. 2007;50:320–4.CrossRefPubMed
43.
go back to reference Farwell WR, Taylor EN. Serum bicarbonate, anion gap and insulin resistance in the National Health and Nutrition Examination Survey. Diabet Med. 2008;25:798–804.CrossRefPubMed Farwell WR, Taylor EN. Serum bicarbonate, anion gap and insulin resistance in the National Health and Nutrition Examination Survey. Diabet Med. 2008;25:798–804.CrossRefPubMed
44.
go back to reference Farwell WR, Taylor EN. Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey. CMAJ. 2010;182:137–41.CrossRefPubMedPubMedCentral Farwell WR, Taylor EN. Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey. CMAJ. 2010;182:137–41.CrossRefPubMedPubMedCentral
45.
go back to reference Lundblad R. Considerations for the use of blood plasma and serum for proteomic analysis. Int J Genomics Proteomics. 2003;1(2):58. Lundblad R. Considerations for the use of blood plasma and serum for proteomic analysis. Int J Genomics Proteomics. 2003;1(2):58.
46.
go back to reference Robinson MD. Novel diagnostic and analytical applications of benchtop time-domain NMR. Greenville: East Carolina University; 2015. Robinson MD. Novel diagnostic and analytical applications of benchtop time-domain NMR. Greenville: East Carolina University; 2015.
48.
49.
go back to reference Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Proinsulin as a marker for the development of NIDDM in Japanese–American men. Diabetes. 1995;44:173–9.CrossRefPubMed Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Proinsulin as a marker for the development of NIDDM in Japanese–American men. Diabetes. 1995;44:173–9.CrossRefPubMed
50.
go back to reference Mykkanen L, Haffner SM, Kuusisto J, Pyorala K, Hales CN, Laakso M. Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia. 1995;38:1176–82.CrossRefPubMed Mykkanen L, Haffner SM, Kuusisto J, Pyorala K, Hales CN, Laakso M. Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia. 1995;38:1176–82.CrossRefPubMed
51.
go back to reference Hanley AJ, D’Agostino R Jr, Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM, Insluin Resistance Atrherosclerosis Study. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes. 2002;51:1263–70.CrossRefPubMed Hanley AJ, D’Agostino R Jr, Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM, Insluin Resistance Atrherosclerosis Study. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes. 2002;51:1263–70.CrossRefPubMed
52.
go back to reference Pfutzner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lubben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004;27:682–7.CrossRefPubMed Pfutzner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lubben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004;27:682–7.CrossRefPubMed
53.
go back to reference Pfutzner A, Forst T. Elevated intact proinsulin levels are indicative of beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol. 2011;5:784–93.CrossRefPubMedPubMedCentral Pfutzner A, Forst T. Elevated intact proinsulin levels are indicative of beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol. 2011;5:784–93.CrossRefPubMedPubMedCentral
54.
go back to reference Schuhmacher JH, Conrad D, Manke HG, Clorius JH, Matys ER, Hauser H, Zuna I, Maier-Borst W, Hull WE. Investigations concerning the potential for using 1H NMR relaxometry or high-resolution spectroscopy of plasma as a screening test for malignant lung disease. Magn Reson Med. 1990;13:103–32.CrossRefPubMed Schuhmacher JH, Conrad D, Manke HG, Clorius JH, Matys ER, Hauser H, Zuna I, Maier-Borst W, Hull WE. Investigations concerning the potential for using 1H NMR relaxometry or high-resolution spectroscopy of plasma as a screening test for malignant lung disease. Magn Reson Med. 1990;13:103–32.CrossRefPubMed
55.
go back to reference Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. 2005;54:570–5.CrossRefPubMed Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. 2005;54:570–5.CrossRefPubMed
56.
go back to reference Ginsberg HN, Zhang Y, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity. 2006;14:41S–9S.CrossRefPubMed Ginsberg HN, Zhang Y, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity. 2006;14:41S–9S.CrossRefPubMed
57.
go back to reference Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol. 2012;32:1754–9.CrossRefPubMed Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol. 2012;32:1754–9.CrossRefPubMed
60.
go back to reference Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–94.CrossRefPubMed Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–94.CrossRefPubMed
61.
go back to reference Biessels GJ. Capitalising on modifiable risk factors for Alzheimer’s disease. Lancet Neurol. 2015;13:752–3.CrossRef Biessels GJ. Capitalising on modifiable risk factors for Alzheimer’s disease. Lancet Neurol. 2015;13:752–3.CrossRef
62.
go back to reference De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014;63:2262–72.CrossRefPubMed De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014;63:2262–72.CrossRefPubMed
63.
go back to reference Willette AA, Bendlin BB, Starks EJ, et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for alzheimer disease. JAMA Neurol. 2015;72:1013–20.CrossRefPubMedPubMedCentral Willette AA, Bendlin BB, Starks EJ, et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for alzheimer disease. JAMA Neurol. 2015;72:1013–20.CrossRefPubMedPubMedCentral
64.
go back to reference Li TC, Yang CP, Tseng ST, Li CI, Liu CS, Lin WY, Hwang KL, Yang SY, Chiang JH,Lin CC. Visit-to-visit variations in fasting plasma glucose and HbA1c associated with an increased risk of Alzhemier Disease: Taiwan Diabetes Study. Diabetes Care. 2017;40(9):1210-7.CrossRefPubMed Li TC, Yang CP, Tseng ST, Li CI, Liu CS, Lin WY, Hwang KL, Yang SY, Chiang JH,Lin CC. Visit-to-visit variations in fasting plasma glucose and HbA1c associated with an increased risk of Alzhemier Disease: Taiwan Diabetes Study. Diabetes Care. 2017;40(9):1210-7.CrossRefPubMed
65.
go back to reference Blumich B, Haber-Pohlmeier S, Wasif Z. Compact NMR. Boston: De Gruyter; 2014.CrossRef Blumich B, Haber-Pohlmeier S, Wasif Z. Compact NMR. Boston: De Gruyter; 2014.CrossRef
66.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
67.
go back to reference Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–95.CrossRefPubMed Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–95.CrossRefPubMed
68.
go back to reference Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet. 1995;346:120–1.CrossRefPubMed Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet. 1995;346:120–1.CrossRefPubMed
69.
go back to reference Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.CrossRefPubMed Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.CrossRefPubMed
70.
go back to reference Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–8.PubMed Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–8.PubMed
71.
go back to reference Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1986;128:181–209.CrossRefPubMed Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1986;128:181–209.CrossRefPubMed
Metadata
Title
Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study
Authors
Michelle D. Robinson
Ina Mishra
Sneha Deodhar
Vipulkumar Patel
Katrina V. Gordon
Raul Vintimilla
Kim Brown
Leigh Johnson
Sid O’Bryant
David P. Cistola
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1359-5

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.